BIONTECH SE |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 75.25 EUR | -0.86% |
|
-4.81% | -20.81% |
| 28/06 | European Equities Traded in the US as American Depositary Receipts Nudge Higher in Friday Trading | MT |
| 28/06 | Pfizer: CHMP recommends new Covid vaccine | CF |
| Sales 2024 * | 2.75B 2.94B 245B | Sales 2025 * | 2.74B 2.93B 245B | Capitalization | 18.1B 19.39B 1,617B |
|---|---|---|---|---|---|
| Net income 2024 * | -419M -449M -37.42B | Net income 2025 * | -548M -587M -48.95B | EV / Sales 2024 * | 1.98 x |
| Net cash position 2024 * | 12.67B 13.58B 1,132B | Net cash position 2025 * | 12.02B 12.87B 1,074B | EV / Sales 2025 * | 2.22 x |
| P/E ratio 2024 * |
-41.4
x | P/E ratio 2025 * |
-32.8
x | Employees | 6,133 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.48% |
More Fundamentals
* Assessed data
More news
Latest transcript on BioNTech SE
More recommendations
More press releases
More news
| 1 day | -0.86% | ||
| 1 week | -4.81% | ||
| Current month | -18.43% | ||
| 1 month | -13.11% | ||
| 3 months | -12.60% | ||
| 6 months | -21.57% | ||
| Current year | -20.81% |
1 week
74.90
81.05
1 month
74.9095.90
Current year
74.90103.90
1 year
74.90115.95
3 years
74.90395.00
5 years
65.50395.00
10 years
65.50395.00
| Managers | Title | Age | Since |
|---|---|---|---|
Ugur Sahin
CEO | Chief Executive Officer | 58 | 02/08/02 |
Özlem Türeci
FOU | Founder | 57 | 02/08/02 |
Jens Holstein
DFI | Director of Finance/CFO | 60 | 01/21/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Rudolf Staudigl
BRD | Director/Board Member | 70 | 01/22/01 |
| Director/Board Member | 67 | 02/08/02 | |
Helmut Jeggle
CHM | Chairman | 53 | 02/08/02 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 28/24/28 | 75.25 | -0.86% | 28,698 |
| 27/24/27 | 75.9 | -2.19% | 45,309 |
| 26/24/26 | 77.6 | -2.76% | 31,658 |
| 25/24/25 | 79.8 | -1.36% | 19,760 |
| 24/24/24 | 80.9 | +2.34% | 71,845 |
Delayed Quote Xetra, June 28, 2024 at 09:05 pm IST
More quotes
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Calendar
05/08/2024
- Q2 2024 Earnings Call
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
75
EUR
Average target price
103.5
EUR
Spread / Average Target
+38.03%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +15.20% | 121B | |
| +19.67% | 113B | |
| +18.95% | 26.02B | |
| -19.03% | 15.91B | |
| -20.90% | 15.09B | |
| -46.14% | 15.06B | |
| +63.85% | 14.93B | |
| +4.49% | 13.85B | |
| +116.20% | 10.8B |
- Stock Market
- Equities
- BNTX Stock
- 22UA Stock
